PROM1 and osteosarcoma: Gui et al. [220] developed polymer-lipid nanoparticles (PLNP) modified with CD133 aptamers for targeted delivery of all-trans retinoic acid (ATRA) (ATRA-PLNP-CD133) to osteosarcoma initiating cells (Figure 13).